Amgen T-VEC’s Remaining Challenges: Getting To Market, Staying Relevant
Executive Summary
After overwhelming but unenthusiastic endorsement from FDA’s advisory committee, the metastatic melanoma immunotherapy could still be hobbled by problematic trials as Amgen seeks approval path and prescriptions in rapidly changing disease space.